Deutsche Bank AG Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Deutsche Bank AG lessened its stake in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 91.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,433 shares of the company’s stock after selling 290,286 shares during the quarter. Deutsche Bank AG owned approximately 0.07% of Lifecore Biomedical worth $189,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Prudential Financial Inc. purchased a new stake in Lifecore Biomedical in the fourth quarter worth $95,000. Wells Fargo & Company MN lifted its stake in Lifecore Biomedical by 29.0% in the fourth quarter. Wells Fargo & Company MN now owns 13,381 shares of the company’s stock worth $99,000 after acquiring an additional 3,012 shares during the period. MetLife Investment Management LLC purchased a new stake in Lifecore Biomedical in the fourth quarter worth $108,000. Lepercq Multi Asset Fund purchased a new stake in Lifecore Biomedical in the fourth quarter worth $169,000. Finally, Steward Partners Investment Advisory LLC lifted its stake in Lifecore Biomedical by 61.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 27,184 shares of the company’s stock worth $202,000 after acquiring an additional 10,320 shares during the period. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Insider Buying and Selling at Lifecore Biomedical

In other news, major shareholder Aron R. English sold 15,847 shares of the firm’s stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $7.01, for a total transaction of $111,087.47. Following the completion of the transaction, the insider now directly owns 1,714,070 shares in the company, valued at $12,015,630.70. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 1,485,182 shares of company stock valued at $9,824,031. 32.20% of the stock is currently owned by company insiders.

Lifecore Biomedical Stock Performance

Shares of LFCR stock opened at $6.87 on Tuesday. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21. The firm has a market capitalization of $254.36 million, a price-to-earnings ratio of -12.27 and a beta of 0.65. The stock has a fifty day moving average of $6.52 and a 200 day moving average of $6.57. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $7.99.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings data on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $35.15 million for the quarter, compared to analysts’ expectations of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. As a group, research analysts expect that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, William Blair started coverage on Lifecore Biomedical in a research note on Wednesday, May 21st. They issued an “outperform” rating for the company.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.